Brief: Pharvaris Announces Positive Top-Line Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks

Pharvaris NV

08/12/2022 13:14

Dec 8 (Reuters) - Pharvaris NV  PHVS.O :
    * PHARVARIS ANNOUNCES POSITIVE TOP-LINE PHASE 2 DATA FROM
RAPIDE-1
STUDY OF PHVS416 FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS
    * PHARVARIS NV - PRIMARY ENDPOINT MET, SUBSTANTIALLY
REDUCING HAE
ATTACK SYMPTOMS
    * PHARVARIS NV - ALL SECONDARY ENDPOINTS MET
    * PHARVARIS NV - PHVS416 WAS WELL TOLERATED AT ALL DOSE
LEVELS

Source text for Eikon:  ID:nGNX7r8PV9 
Further company coverage:  PHVS.O